Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biotricity Inc (NQ: BTCY )

0.7756 +0.0456 (+6.25%)
Streaming Delayed Price Updated: 3:40 PM EDT, Jul 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biotricity Inc

< Previous 1 2 3 4 Next >
Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program
Via ACCESSWIRE
Biotricity Launches HeartSecure: Immediate, At-Home Cardiac Screening Now Available
Via ACCESSWIRE
Biotricity Reports Strong Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses for Fiscal Year 2024, Accelerating the Company's Path to Profitability
Via ACCESSWIRE
Biotricity to Host Fourth Quarter and Fiscal Year 2024 Financial Results and Business Update Call on June 27
Via ACCESSWIRE
Biotricity Launches Direct-to-Consumer Heart Health Screening Service, HeartSecure, Making Heart Health Services Accessible in Response to the #1 Global Killer, Poising Company to Access the Growing Home Diagnostics Market
Via ACCESSWIRE
Biotricity Provides Year-End Guidance with Expectations to Meet Analyst Revenue Target and Beating Loss and Margin Targets
Via ACCESSWIRE
Biotricity Receives Health Canada Clearance for Biotres
Via ACCESSWIRE
Biotricity Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 billion Heartbeats
Via ACCESSWIRE
Biotricity Preferred Shareholders Show Increased Commitment and Support of the Company by Converting Almost All Preferred A Shares into Restricted Common Stock
Via ACCESSWIRE
Biotricity Announces the Upcoming Launch of the First-Ever Direct-to-Patient Cardiac Screening Service, Targeting the $1.05B Home Heart Health Market
Via ACCESSWIRE
Biotricity Expands Market Reach to Pulmonary and Neurology Fields Through Latest Partnerships with Two Leading Home-Based Diagnostic Companies
Via ACCESSWIRE
Biotricity's Path Towards Breakeven Accelerated by Latest Diagnostic Product, Biotres Pro, Garnering Rapid Interest from Existing and New Customers
Via ACCESSWIRE
Biotricity to Host Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 14th
Via ACCESSWIRE
CORRECTION BY SOURCE: Biotricity Announces Patent Filing for Cutting-Edge Biotres Device
Via ACCESSWIRE
Biotricity Unveils a New Digital Presence, Highlighting its Expanding Technology Portfolio and Cutting-Edge Innovations
Via ACCESSWIRE
Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics
Via ACCESSWIRE
Biotricity Launches Cardiac Monitoring Pilot Program with Major Hospital Network
Via ACCESSWIRE
Biotricity Announces a Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities
Via ACCESSWIRE
LOBO EV and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Biotricity Accelerates Market Access by Partnering with Third Major Group Purchasing Organization, Expanding Market Reach to 90% of U.S. Hospitals
Via ACCESSWIRE
Biotricity Partners with Health Aid Africa to Provide Complementary Heart Health Screenings at Allegiant Stadium Concert
Via ACCESSWIRE
Biotricity Unveils that Improved Margins Resulted from Latest Advancements to its Proprietary Cardiac AI Cloud Platform and Announces Plans for Continued Expansion of its Cardiac AI Cloud
Via ACCESSWIRE
Biotricity Partners with a Second Top Group Purchasing Organization - Positions Company for Expanded Market Access to 1 out of every 2 Hospitals in America
Via ACCESSWIRE
Biotricity Strengthens its Foundation for Growth, Achieves Lower Cost of Sales, Expanding Margins of 73% and Increased Device Sales, for Third Quarter of Fiscal Year 2024
Via ACCESSWIRE
Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21st
Via ACCESSWIRE
Biotricity Advances Towards Breakeven Milestone - Set to Announce Record Margins and Operational Efficiency for Third Quarter of Fiscal Year 2024
Via ACCESSWIRE
Biotricity Delivers Record Margins and Double Digit Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2024
Via ACCESSWIRE
Biotricity Releases Another Groundbreaking Product: Biotres Pro
Via ACCESSWIRE
Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device
Via ACCESSWIRE
Biotricity Announces Patient Filing for Cutting-Edge Biotres Device
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.